公开(公告)号：US20230158108A1

公开(公告)日：2023-05-25

申请号：US17923180

申请日：2021-05-04

Applicant: University of Utah Research Foundation

Inventor： Christian Con Yost ,  Joshua D. Schiffman

IPC: A61K38/17 ,  A61P29/00

CPC classification number: A61K38/1709 ,  A61P29/00

Abstract: Disclosed are methods for treating neutrophil extracellular trap (NET) mediated inflammatory tissue damage in a patient having COVID-19, comprising administering to the patient having COVID-19 an effective amount of a pharmaceutical composition comprising a NET-inhibitory peptide (NIP) and a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the NET-mediated inflammatory tissue damage Disclosed are methods for inhibiting NET formation in a patient having COVID-19 comprising administering to the patient having COVID-19 an effective amount of a pharmaceutical composition comprising a NIP and a pharmaceutically acceptable carrier to substantially inhibit NET formation.

公开(公告)号：US11324801B2

公开(公告)日：2022-05-10

申请号：US16908250

申请日：2020-06-22

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich ,  Joshua Schiffman

IPC: A61K38/00 ,  A61K38/17 ,  C07K14/47 ,  A61P29/00 ,  A61P35/04

Abstract: Neonatal NET-inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.

公开(公告)号：US10646556B2

公开(公告)日：2020-05-12

申请号：US16255545

申请日：2019-01-23

Applicant: University of Utah Research Foundation

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/57 ,  A61K38/17 ,  C07K14/47 ,  A61K38/00

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US20190307865A1

公开(公告)日：2019-10-10

申请号：US16255545

申请日：2019-01-23

Applicant: University of Utah Research Foundation

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/57 ,  C07K14/47 ,  A61K38/17

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US20210138033A1

公开(公告)日：2021-05-13

申请号：US16908250

申请日：2020-06-22

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich ,  Joshua Schiffman

IPC: A61K38/17 ,  C07K14/47 ,  A61P29/00 ,  A61P35/04

Abstract: Neonatal NET-inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.

公开(公告)号：US10232023B2

公开(公告)日：2019-03-19

申请号：US15441982

申请日：2017-02-24

Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/00 ,  A61K38/57 ,  A61K38/17 ,  C07K14/47

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US20230381290A1

公开(公告)日：2023-11-30

申请号：US18449457

申请日：2023-08-14

Applicant: University of Utah Research Foundation

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/57 ,  A61K38/17 ,  C07K14/47

CPC classification number: A61K38/57 ,  A61K38/1709 ,  C07K14/4703 ,  Y02A50/30 ,  A61K38/00

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US20170232081A1

公开(公告)日：2017-08-17

申请号：US15441982

申请日：2017-02-24

Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/57

CPC classification number: A61K38/57 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/4703 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/473

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US11752203B2

公开(公告)日：2023-09-12

申请号：US16841221

申请日：2020-04-06

Applicant: University of Utah Research Foundation

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/00 ,  A61K38/57 ,  A61K38/17 ,  C07K14/47

CPC classification number: A61K38/57 ,  A61K38/1709 ,  C07K14/4703 ,  A61K38/00 ,  Y02A50/30

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US10857201B2

公开(公告)日：2020-12-08

申请号：US16328697

申请日：2017-09-05

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich ,  Joshua Schiffman

IPC: A61K38/00 ,  A61K38/17 ,  C07K14/47 ,  A61P29/00 ,  A61P35/04

Abstract: Neonatal NET-Inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.